- Home
- REPL vs NATH Comparison
REPL vs NATH Comparison
Compare REPL & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- NATH
- Stock Information
- Founded
- REPL 2015
- NATH 1916
- Country
- REPL United States
- NATH United States
- Employees
- REPL N/A
- NATH N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- NATH Restaurants
- Sector
- REPL Health Care
- NATH Consumer Discretionary
- Exchange
- REPL Nasdaq
- NATH Nasdaq
- Market Cap
- REPL 547.0M
- NATH 442.2M
- IPO Year
- REPL 2018
- NATH N/A
- Fundamental
- Price
- REPL $5.71
- NATH $107.23
- Analyst Decision
- REPL Hold
- NATH
- Analyst Count
- REPL 9
- NATH 0
- Target Price
- REPL $7.00
- NATH N/A
- AVG Volume (30 Days)
- REPL 2.1M
- NATH 28.3K
- Earning Date
- REPL 11-11-2025
- NATH 11-06-2025
- Dividend Yield
- REPL N/A
- NATH 1.85%
- EPS Growth
- REPL N/A
- NATH 9.62
- EPS
- REPL N/A
- NATH 5.77
- Revenue
- REPL N/A
- NATH $150,413,000.00
- Revenue This Year
- REPL N/A
- NATH N/A
- Revenue Next Year
- REPL $408.25
- NATH N/A
- P/E Ratio
- REPL N/A
- NATH $18.70
- Revenue Growth
- REPL N/A
- NATH 6.38
- 52 Week Low
- REPL $2.68
- NATH $74.60
- 52 Week High
- REPL $17.00
- NATH $118.50
- Technical
- Relative Strength Index (RSI)
- REPL 46.92
- NATH 54.03
- Support Level
- REPL $5.60
- NATH $106.29
- Resistance Level
- REPL $6.15
- NATH $110.95
- Average True Range (ATR)
- REPL 0.33
- NATH 2.60
- MACD
- REPL 0.06
- NATH 0.08
- Stochastic Oscillator
- REPL 32.48
- NATH 57.09
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About NATH Nathan's Famous Inc.
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.